METABOLISM AND

CIRCULATORY
PROPRIETARY INFORMATION FOR SPECIALISTS.

LIPOHELP

Lipid control

CARDIOVASCULAR LIPID PROFILE TISSUE

PROTECTION
Cardiovascular diseases (CVD) cause
annually a mortality of 4 million people
in Europe

Of this figure, women represent 55% and men 45%,

although the mortality associated with cardiovas- NORMAL ARTERY
cular diseases before the age of 65 is more
common in men. The mortality and morbidity is in-
creasing with the increase of the prevalence of
risk factors, such as increased blood lipids and
blood pressure, diabetes, obesity… etc.
Hypercholesterolemia is one of the risk factors,
whose incidence is highly associated with the BLOOD FLOW
cardiovascular diseases. During the atherosclerotic
process, cholesterol, mainly in the form of low ATHEROSCLEROSIS
density lipoprotein (LDL), accumulates in the BLOCKED ARTERY BY THE PLAQUE

walls of the arteries, forming atherosclerotic

plaque that later it can be the cause of the arterial
ATHEROSCLEROTIC
block. Epidemiological studies have shown a direct PLAQUE
correlation between LDL-C and the risk of
atherosclerosis and myocardial heart attack. The
reduction of total cholesterol and LDL-C plasma
levels is a set and effective approach for BLOOD FLOW

preventing the risk of coronary events. Several

meta-analyses indicate that a reduction of LDL-C of 1 mmol/ L is associated with a
reduction of 20% to 23% of the risks of coronary and vascular diseases. As long as
there are no other risk factors, the LDL-C levels of ≥ 4.14 mmol/ L are considered as high
levels, and therefore, they should be reduced.
The prevention is defined as a coordinated set of actions, at the population level or
directed to an individual, aimed at eradicating, eliminating or minimising the impact of
cardiovascular diseases and their related disability. The importance of the prevention
of cardiovascular diseases is undeniable and should be considered at different levels: i)
at the general population level, promoting a healthy lifestyle and ii) at the individual
level, in patients with moderate or high-risk CVD or those with defined CVD, due to
approaching an unhealthy lifestyle (e.g. low-quality diet, physical inactivity, smoking)
and for reducing the risk factors, such as increased blood lipids or blood pressure.
The prevention is effective in reducing the impact of cardiovascular diseases; the
elimination of risk-taking behaviour for health, which leads to a prevention of at least
80% of cardiovascular diseases.

THE RED YEAST RICE is a dietary supplement, whose process involves the fermentation
of the yeast Monascus purpureus in the rice. The monacolins act as reversible inhibitors
for 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in
cholesterol biosynthesis, having the same mechanism of action as the statins. In addition
to the inhibition of HMG-CoA reductase, it has been found that red yeast rice contains
sterols (β-sitosterol, camp sterol, stigma sterol and sapogenin), isoflavones, glycosides of
isoflavones and monounsaturated fatty acids. All these are capable of reducing the low
density lipoproteins (LDL-C).

02
 OPTIMISES THE LIPID
METABOLISM
16,23,12,24,29,8,27,32

THE GUIDE OF
EUROPEAN
CARDIOLOGY AND
The combined action
MAIN BENEFITS

ARTERIOSCLEROSIS
SOCIETIES
of the components of RECOMMENDS THE
RED YEAST RICE FOR
LIPOHELP improves THE TREATMENT OF
THE DYSLIPIDEMIA10
and maintains the
levels of the lipid
profile, preventing
the cardiovascular INTEGRAL
risk PROTECTION DUE TO
ITS POWERFUL
ANTIOXIDANT
EFFECT 7,26,21,18

CONVENIENT DOSAGE:
TWO VEGETABLE
CAPSULES PER DAY
03
LIPOHELP has been developed for the
improvement and maintenance of the levels of
the lipid profile, preventing the cardiovascular
risk
Action of ingredients:
REDUCES THE LEVELS OF LIPIDS IN JUST 4
1. WEEKS4,14,21,23,24,25,31,34,35
Reduces the levels of total cholesterol in 22.7%, LDL-C in 29.4%,
non-HDL-C in 29.8%.
Decrease of the caloric intake and adiposity.

RED YEAST RICE

(Monascus purpureus)* INHIBITS THE HMG COA
contains polyketide, REDUCTASES, AN ENZYME
unsaturated fatty acids, THAT INCREASES THE
phytosterols and monacolins. SYNTHESIS OF CHOLESTEROL

*Provides a minimum of 10mg of monacolin K

BLACK PEPPER
(Piper nigrum)
Standardised in piperine MODULATES THE LIPOGENESIS
Contains polyphenols, alkaloids, terpenes
and tannins

REDUCES THE REABSORPTION

OF BILE ACIDS, INCREASING
PECTIN THE SYNTHESIS OF BILE
Complex polysaccharide ACIDS FROM CHOLESTEROL

04
 DECREASES THE RISK OF ENDOTHELIAL
2. DAMAGE13,22,32,33
Effective capture of the main free radicals, reducing the lipid
oxidation
Contributes to an improved vascular tonicity, avoiding the thrombosis
formation

POLICOSANOL INHIBITS THE PLATELET

Contains a mixture of aliphatic long AGGREGATION
chain alcohols

REGULATES THE PRODUCTION

CITRIC BIOFLAVONOIDS OF LIPOPROTEINS, REDUCING
Standardised in hesperidin
THE PROGRESSION OF
Contains flavones ATHEROSCLEROSIS

3. REGULATES THE BLOOD SUGAR LEVEL 4,5,7,21

MILK THISTLE MODULATE THE GLUCOSE

(Silybum marianum) METABOLISM AT A HEPATIC
Standardised in silymarin LEVEL
Contains flavonolignans

REDUCE IN 13% THE PLASMA

GLUCOSE AND IN 20% THE
PECTIN INSULIN REQUIREMENTS, IN
TYPE 2 DIABETIC PATIENTS
BLACK PEPPER

PROTECTS TISSUES AND ORGANS DUE TO ITS

4. ANTIOXIDANT EFFECT11,15,18,26,29

ACEROLA (Malpighia glabra)

Standardised in vitamin C
Contains vitamin C, polyphenols and IMPROVES THE HEPATIC
carotenoids METABOLISM AND REDUCES
THE VASCULAR REMODELLING

CITRIC BIOFLAVONOIDS POWERFUL ANTIOXIDANT AND

ANTI-INFLAMMATORY ACTION
MILK THISTLE

05
 VEGETABLE
CAPSULES

2 capsules per day

LIPOHELP / 60 VEGETABLE CAPSULES

ACTIVE INGREDIENTS PER 2 CAPSULES

Red yeast rice* (Monascus purpureus) 666 mg
Milk thistle 150 mg
Black pepper 40 mg
Acerola 40 mg
Pectin 40 mg
Policosanol 40 mg
Citrus bioflavonoids 33.4 mg
*Provides a minimum of 10 mg of Monacolin K

Proprietary Information for specialists. The distribution of this document, in whole or in part, is strictly prohibited.

1. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol
to Reduce Atherosclerotic Cardiovascular Risk in Adults. A Report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines. Journal of the American College
of Cardiology, Vol. 63, No. 25, 2014.
2. Arrigo F G Cicero, Martino Morbini, Angelo Parini et al. Effect of
red yeast rice combined with antioxidants on lipid pattern, hs-CRP
level, and endothelial function in moderately hypercholesterolemic
subjects. Therapeutics and Clinical Risk Management 2016:12 281–286.
3. Benito F. García et al. Synergy and Other Interactions between Poly-
methoxyflavones from Citrus Byproducts. Molecules 2015, 20,
20079–20106.
4. Brahma Naidu Parim et al. Effects of Piper nigrum extracts: Restora-
tive perspectives of high-fat diet-induced changes on lipid profile,
body composition, and hormones in Sprague–Dawley rats. Pharm
Biol, 2015; 53(9): 1318–1328.
5. Carmen Tamayo, MD, and Suzanne Diamond, MSc. Review of Clinical
Trials Evaluating Safety and Efficacy of Milk Thistle (Silybum marianum
[L.] Gaertn.)
6. Cheng-Chieh Lin et al. Efficacy and safety of Monascus purpureus
Went rice in subjects with hyperlipidemia. European Journal of Endo-
crinology (2005) 153 679–686.
7. Christos E. Kazazis et al. The Therapeutic Potential of Milk Thistle
in Diabetes. The Review of Diabetic Studies Vol 11 No 2 2014.
8. Clare L. Adam et al. Soluble Fermentable Dietary Fibre (Pectin)
Decreases Caloric Intake, Adiposity and Lipidaemia in High-Fat Diet-In-
duced Obese Rats. PLOS ONE | DOI:10.1371/journal.pone.0140392
October 8, 2015.
9. Daisuke Matsuda et al. Molecular Target of Piperine in the Inhibition
of Lipid Droplet Accumulation in Macrophages. Biol. Pharm. Bull. 31(6)
1063—1066 (2008).
10. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
The Task Force for the Management of Dyslipidaemias of the European
Society of Cardiology (ESC) and European Atherosclerosis Society
(EAS). European Heart Journal (2016) 37, 2999–3058Arrigo F G
Cicero et al. Effect of red yeast rice combined with antioxidants on
lipid pattern, hs-CRP level, and endothelial function in moderately
hypercholesterolemic subjects. Therapeutics and Clinical Risk Manage-
ment 2016:12 281–286E.S. Hackett et al. Milk Thistle and Its Derivative
Compounds: A Review of Opportunities for Treatment of Liver Disease.
J Vet Intern Med 2013; 27:10–16.
11. EJ Ladas et al. A randomized controlled, double-blind pilot study
of milk thistle for the treatment of hepatotoxicity in childhood acute
lymphoblastic leukemia (ALL). Cancer. 2010 January 15; 116(2):
506–513.
12. E.S. Hackett, D.C. Twedt, and D.L. Gustafson. Milk Thistle and Its
Derivative Compounds: A Review of Opportunities for Treatment of
Liver Disease. J Vet Intern Med 2013; 27:10–16.
13. Eun-Young Lee et al. Anti-Aging and Tissue Regeneration Ability
of Policosanol Along with Lipid-Lowering Effect in Hyperlipidemic
Zebrafish via Enhancement of High-Density Lipoprotein Functionality.
Rejuvenation Research Volume 19, Number 2, 2016.
14. F. Brouns et al. Cholesterol-lowering properties of different pectin
types in mildly hyper-cholesterolemic men and women. European
Journal of Clinical Nutrition (2012) 66, 591–599.
15. Fernando Milanez Dias et al. Acerola (Malpighia emarginata DC.)
juice intake protects against alterations to proteins involved in inflam-
matory and lipolysis pathways in the adipose tissue of obese mice
fed a cafeteria diet. Lipids in Health and Disease 2014, 13:24.
16. Francesco Di Pierro et al. Retrospective analysis of the effects of
a highly standardized mixture of Berberis aristata, Silybum marianum,
and monacolins K and KA in patients with dyslipidemia. Clinical Phar-
macology: Advances and Applications 2017:9 1–7.
17. Francine Rainone, D.O., Ph.D., M.S. Milk Thistle. American Family
Physician October 1, 2005, Volume 72, Number 7.
18. Julia M. Assini et al. Citrus flavonoids and lipid metabolism. Current
Opinion Volume 24, Number 1, February 2013
19. Leonardo Nogara et al. Piperine’s mitigation of obesity and diabetes
can be explained by its up-regulation of the metabolic rate of resting
muscle. PNAS, November 15, 2016, vol. 113 no. 46: 13009–13014.
20. Limei Wang et al. Piperine inhibits ABCA1 degradation and promo-
tes cholesterol efflux from THP-1-derived macrophages. Mol. Nutr.
Food Res. 61, 4, 2017, 1500960.
21. Lisa Brown et al. Cholesterol-lowering effects of dietary fiber: a me-
ta-analysis. Am J Clin Nutr 1999; 69:30–42.
22. M. Ashraful Alam et al. Effect of Citrus Flavonoids, Naringin and
Naringenin, on Metabolic Syndrome and Their Mechanisms of Action.
Adv. Nutr. 5: 404–417, 2014.
23. Maaike C. Gerards et al. Traditional Chinese lipid-lowering agent
red yeast rice results in significant LDL reduction but safety is uncer-
tain-A systematic review and meta-analysis. Atherosclerosis 240
(2015) 415-423.
24. R.S. Vijayakumar et al. Antioxidant efficacy of black pepper (Piper
nigrum L.) and piperine in rats with high fat diet induced oxidative
stress. Redox Report, Vol. 9, No. 2, 2004.
25. Ravi R. Kasliwal M.D. et al. ESSENS dyslipidemia: A placebo-contro-
lled, randomized study of a nutritional supplement containing red
yeast rice in subjects with newly diagnosed dyslipidemia. Nutrition
32 (2016) 767–776.
26. Roberta Nunes Horta et al. Protective effects of acerola juice on
genotoxicity induced by iron in vivo. Genetics and Molecular Biology,
39, 1, 122-128 (2016).
27. Stefano Gonnelli MD et al. Efficacy and Tolerability of a Nutraceuti-
cal Combination (Red Yeast Rice, Policosanols, and Berberine) in
Patients with Low-Moderate Risk Hypercholesterolemia: A Dou-
ble-Blind, Placebo-Controlled Study. Current Therapeutic Research
77 (2015) 1–6
28. Sun-Jin Hur et al. The Effects of Biopolymer Encapsulation on
Total Lipids and Cholesterol in Egg Yolk during in Vitro Human Diges-
tion. Int. J. Mol. Sci. 2013, 14, 16333-16347.
29. Takayuki Hanamura et al. Structural and Functional Characteriza-
tion of Polyphenols Isolated from Acerola (Malpighia emarginata DC.)
Fruit. Biosci. Biotechnol. Biochem., 69 (2), 280-286, 2005.
30. Tina Heinz et al. Low daily dose of 3 mg monacolin K from RYR
reduces the concentration of LDL-C in a randomized, placebo-contro-
lled intervention. Nutrition Research 36 (2016) 116–1170.
31. Veronique Verhoeven et al. Red yeast rice lowers cholesterol in phy-
sicians-a double blind, placebo controlled randomized trial. BMC Com-
plementary and Alternative Medicine 2013, 13:178.
32. Wai-Teng Wong et al. Attenuation of Thrombosis by Crude Rice
(Oryza sativa) Bran Policosanol Extract: Ex Vivo Platelet Aggregation
and Serum Levels of Arachidonic Acid Metabolites. Evidence-Based
Complementary and Alternative Medicine Volume 2016, Article ID
7343942, 8 pages.
33. Wai-Teng Wong et al. Modulation of platelet functions by crude
rice (Oryza sativa) bran policosanol extract. BMC Complementary
and Alternative Medicine (2016) 16:252.
34. Xingjiang Xiong et al. The effects of red yeast rice dietary supple-
ment on blood pressure, lipid profile, and C-reactive protein in hyperten-
sion: A systematic review. Journal Critical Reviews in Food Science
and Nutrition, Volume 57, 2017 - Issue 9
35. Yi Chin Ong BPharm and Zoriah Aziz PhD. Review Article Systema-
tic review of red yeast rice compared with simvastatin in dyslipidae-
mia. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 170–179.

MARTINEZ NIETO, S.A.

07-MN105-001

Pol. Ind. Los Camachos Sur - Avda. del Carbono, 96

30369 LOS CAMACHOS - CARTAGENA (SPAIN)
T. (+34) 968 515 080 - F. (+34) 968 534 300
marnys@marnys.com - www.marnys.com